Evidence map›Paper›PMID 39534000›Full record

ReviewAsian journal of urology2024

Efficacy and safety of platelet-rich plasma intracavernous injection for patients with erectile dysfunction: A systematic review, meta-analysis, and meta-regression.

Sally Suharyani, Moses Leonardo, Heru Harsojo Oentoeng, Edwin Raja Pardamean Lumban Tobing, Christiano Tansol, Timotius Ivan Hariyanto

Abstract readReview
In one paragraph

Review in Asian journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sally SuharyaniFaculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
Moses LeonardoFaculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
Heru Harsojo OentoengDepartment of Andrology and Sexual Medicine, Siloam Hospitals Kebon Jeruk, Jakarta, Indonesia.
Edwin Raja Pardamean Lumban TobingDepartment of Urology, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
Christiano TansolDepartment of Urology, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
Timotius Ivan HariyantoFaculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Intracavernous injection might be offered to patients with erectile dysfunction (ED) who did not respond to the first-line oral treatment. Platelet-rich plasma (PRP) might offer improvement in erectile function since it contains numerous growth factors. This study aimed to evaluate the efficacy and safety of PRP intracavernous injection for patients with ED. Methods: We conducted relevant literature searches on Cochrane Library, Medline, Scopus, and ClinicalTrials.gov databases using specific keywords. The results of continuous variables were pooled into the mean difference (MD) and dichotomous variables into the odds ratio along with 95% confidence interval (95% CI). Results: A total of six studies were included. Our pooled analysis revealed that PRP intracavernous injection was associated with a significant increase in the erectile function domain of the International Index of Erectile Function at 1 month (MD 3.47 [95% CI 2.62-4.32], Conclusion: PRP intracavernous injection may offer benefits in improving erectile function in patients with ED with a relatively good safety profile.

Indexed as

Erectile functionPlatelet-rich plasmaSexual dysfunctionTreatmentUrology

Identifiers

PMID39534000
PMCPMC11551376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.